1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E1F95694EE465A7D00258751005A3F84
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-evolving-role-medical-affairs-in-product-launch-timelines-success-factors-and-digital-influence?opendocument
18
19opendocument
203.89.204.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Launch Optimization

The Evolving Role of Medical Affairs in Product Launch: Timelines, Success Factors, and Digital Influence

ID: 5697


Features:

9 Info Graphics

15 Data Graphics

200+ Metrics


Pages/Slides: 35


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "The Evolving Role of Medical Affairs in Product Launch: Timelines, Success Factors, and Digital Influence"

STUDY OVERVIEW

The last decade has seen Medical Affairs move from a support function to a strategic, central function in biopharma. Change has been constant with Medical becoming the hub for insight and intelligence for the company, taking the lead in shaping the evidence agenda, establishing excellence in external engagement and value communication. Additionally, the Covid-19 pandemic has triggered a tsunami of rapid digital technological adoptions for Medical Affairs.


This research explores Medical’s role in product launch. The research probes medical activity timelines, and performance metrics. It further explores critical success factors and digital implementation for launch preparedness.

KEY TOPICS

  • Executive Summary: Methodology, Participants, & Key Findings
  • Launch Timeline, Preparedness Metrics and Resourcing
  • Critical Success Factors and Major Pitfalls
  • Digital Influence on Launch Processes and Launch Tool Deployment

KEY METRICS

  • The time when each Medical group ideally should get involved in product launch activities and when each group actually becomes involved?
  • Indicate the total annual Medical Affairs launch investment in U.S. dollars and number of FTEs for your product in the following years of the launch phase.
  • Do you have a launch dashboard? What information are you using with your dashboard?
  • Indicate the percentage of total Medical Affairs launch investment allocated to each of the following Medical Affair's activities during each time period.
  • What have been the critical success factors that drive successful launch for Medical Affairs?
  • What are the major pitfalls for Medical Affairs during launch?
  • How has pandemic changed digital technology utilization in medical affairs group during product launches?
  • Rate the level of influence on current and future launch processes with the use of digital technology.
  • When are the digital tools deployed by Medical Affairs during product launch cycle?
  • Rate the impact of the following digital activities and programs used to support a successful pharma product launch?
  • What are the top three digital tools that can bring success to Medical Affairs and product launch activities?
SAMPLE KEY FINDINGS
  • Digital: Build a digital tool portfolio designed to track impact and be implemented earlier in the product lifecycle. Digital toolboxes must be adaptable to fit across the lifecycle, even where infrastructure lags.

METHODOLOGY

The study engaged 60 executives from 43 leading life sciences companies. Medical Directors and VPs represent nearly four-fifths of the leaders who shared data and insights on Medical launch activities in this study

Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Biopharmaceutical; Diagnostic; Health Care; Chemical; Consulting; Consumer Products; Clinical Research; Laboratories; Science


Companies Profiled:
Adamas Pharmaceuticals; AstraZeneca; Alcon; Albireo; Apellis Pharmaceuticals; ASC Therapeutics; Baxter Healthcare; BELLUS Health; Boehringer Ingelheim; BIAL; bioMerieux; Cardinal Health; Cipla; Eisai; EMD Serono; Genentech; Fidia; Eurofarma; GlaxoSmithKline ; GW Pharmaceuticals; Ipsen; Helsinn; Karyopharm Therapeutics; Kyowa Kirin; Labaid Group; Matinas BioPharma; Lundbeck; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck Serono; NextGen Healthcare; Novartis; Pfizer; Pixacore; Gedeon Richter ; Sandoz; Sanofi; Santen; Sunovion; Takeda Pharmaceuticals; Thermo Fisher; Terumo Corporation; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.